



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  A61K 31/40, 31/445, 31/435		A1	(11) International Publication Number: <b>WO 93/12785</b>  (43) International Publication Date: 8 July 1993 (08.07.93)		
(21) International Application Number: PCT/GB92/02376  (22) International Filing Date: 21 December 1992 (21.12.92)		(74) Agent: JONES, Pauline; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).			
(30) Priority data:  9127184.1 21 December 1991 (21.12.91) GB 9127185.8 21 December 1991 (21.12.91) GB 9219354.9 12 September 1992 (12.09.92) GB		(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
(71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		Published <i>With international search report.</i>			
(72) Inventors; and (75) Inventors/Applicants (for US only): SANGER, Gareth, John [GB/GB]; WARDLE, Kay, Alison [GB/GB]; Smith-Kline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).					
(54) Title: USE OF 5-HT <sub>4</sub> MODULATORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF THE BLADDER DISEASES					
(57) Abstract					
A compound which acts as an antagonist at 5-HT <sub>4</sub> receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT <sub>4</sub> receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostatectomy.					

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Bulgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Mongoco	TC	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam

Use of 5-HT<sub>4</sub> modulators for the manufacture of a medicament for the treatment of the bladder diseases

This invention relates to treatment of conditions associated with bladder

5 hypersensitivity, and conditions associated with a poorly functioning bladder.

European Journal of Pharmacology 146 (1988), 187-188, and Naunyn-Schmiedeberg's Arch. Pharmacol. (1989) 340:403-410, describe a non classical 5-hydroxytryptamine receptor, now designated the 5-HT<sub>4</sub> receptor, 10 and that tropisetron (ICS 205-930), which is also a 5-HT<sub>3</sub> receptor antagonist, acts as an antagonist at this receptor and metoclopramide is an agonist at this receptor.

WO 91/16045 (SmithKline and French Laboratories Limited) describes the 15 use of cardiac 5-HT<sub>4</sub> receptor antagonists in the treatment of atrial arrhythmias and stroke.

Metoclopramide has been shown to be effective in treating a poorly 20 functioning bladder, (Scand. J. Urology and Nephrology, 13:79-82 (1979) but this has not been specifically linked to any known action of metoclopramide.

There are reports in the literature of 5-HT<sub>4</sub> receptors potentiating contractions in human bladder (Br. J. Pharmacol, 61, 115P) and inhibiting contractions in monkey bladder (2nd International Symposium on Serotonin, Houston, 25 September 1992, page 86).

We have now discovered that a compound which acts as an antagonist at 30 5-HT<sub>4</sub> receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT<sub>4</sub> receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostatectomy. When used herein the term '5-HT<sub>4</sub> modulator' is used to denote antagonists and agonists.

35

The invention therefore provides a method for the treatment and/or prophylaxis of conditions associated with bladder hypersensitivity and conditions associated with a poorly functioning bladder in mammals, including

- 2 -

humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis, an effective and/or prophylactic amount of a 5-HT<sub>4</sub> modulator.

5 5-HT<sub>4</sub> modulators may be identified according to standard methods, such as those described hereinafter, and that described in Naunyn-Schmiedeberg's Arch Pharmacol. 342, 619-622.

Examples of 5-HT<sub>4</sub> receptor antagonists include ICS 205-930 (tropisetron - 10 Sandoz), R 50 595 (Janssen), which is described in FR 76530 and Eur.J. Pharmacol., 181 119-125 (1990), and SDZ 205-557, which is described by K.H. Buchheit and R. Gamse in Naunyn-Schmiedeberg's Arch. Pharmacol., 343 (Suppl.), R101 (1991). DAU 6285 (Naunyn-Schmiedeberg's Arch. Pharmacol., 345; 264-269 (1992) and RS 23597-190 (Syntex - British 15 Pharmacology Society Meeting, September 1992).

EP-A-501322 (Glaxo Group Limited) describes indole derivatives having 5-HT<sub>4</sub> receptor antagonist activity and reports 5-HT<sub>4</sub> receptors are believed to be associated with conditions involving *inter alia* the urinary tract (e.g. 20 urinary incontinence).

Examples of 5-HT<sub>4</sub> receptor agonists include cisapride, renzapride and zacopride.

25 In one aspect, the 5-HT<sub>4</sub> modulator is more potent at 5-HT<sub>4</sub> receptors than at 5-HT<sub>3</sub> receptors.

Preferably, the 5-HT<sub>4</sub> modulator is in substantially pure pharmaceutically acceptable form.

30 The administration of the 5-HT<sub>4</sub> modulator may be by way of oral, sublingual, transdermal or parenteral administration.

An amount effective to treat the disorder hereinbefore described depends on 35 the usual factors such as the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose will normally contain 0.1 to 50 mg for example 0.5 to 10 mg, of the 5-HT<sub>4</sub> modulator. Unit doses will normally be administered once or more than once a day, for example 2, 3,

- 3 -

or 4 times a day, more usually 1 to 3 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 50 mg, for example 0.1 to 5 mg, that is in the range of approximately 0.001 to 1 mg/kg/day, more usually 0.005 to 0.2 mg/kg/day.

5

For oral or parenteral administration, it is greatly preferred that the 5-HT<sub>4</sub> modulator is administered in the form of a unit-dose composition, such as a unit dose oral or parenteral composition.

10 Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusible solutions or suspensions or suppositories.

15

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known

20 methods in the art.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for 25 example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

These solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to 30 distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as 35 a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or

- 4 -

hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example 5 methyl or propyl  $\alpha$ -hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.

10 For parenteral administration, fluid unit dose forms are prepared containing the 5-HT<sub>4</sub> modulator and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a 15 vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

20 Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included 25 in the composition to facilitate uniform distribution of the compound of the invention.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the treatment concerned.

30 The present invention also provides the use of a 5-HT<sub>4</sub> modulator in the manufacture of a medicament for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity. Such treatment and/or prophylaxis may be carried out as 35 hereinbefore described.

- 5 -

The present invention further provides a pharmaceutical composition for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity, which comprises a 5-HT<sub>4</sub> modulator, and a pharmaceutically acceptable carrier. Such compositions 5 may be prepared in the manner as hereinbefore described.

### 5-HT<sub>4</sub> modulator activity

10

#### 1) Guinea pig colon

Male guinea-pigs, weighing 250-400g are used. Longitudinal muscle-myenteric plexus preparations, approximately 3cm long, are obtained from 15 the distal colon region. These are suspended under a 0.5g load in isolated tissue baths containing Krebs solution bubbled with 5% CO<sub>2</sub> in O<sub>2</sub> and maintained at 37°C. In all experiments, the Krebs solution also contains methiothepin 10<sup>-7</sup>M and granisetron 10<sup>-6</sup>M to block effects at 5-HT<sub>1</sub>, 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors.

20

After construction of a simple concentration-response curve with 5-HT, using 30s contact times and a 15min dosing cycle, a concentration of 5-HT is selected so as to obtain a contraction of the muscle approximately 40-70% maximum(10-9M approx). The tissue is then alternately dosed every 15min 25 with this concentration of 5-HT and then with an approximately equi-effective concentration of the nicotine receptor stimulant, dimethylphenylpiperazinium (DMPP). After obtaining consistent responses to both 5-HT and DMPP, increasing concentrations of a putative 5-HT<sub>4</sub> modulator are then added to the bathing solution. The effects of this compound are then determined as a 30 percentage reduction of the contractions evoked by 5-HT or by DMPP.

From this data, IC<sub>50</sub> values are determined, being defined as the concentration of antagonist or agonist which reduces or increases the contraction by 50%. A compound which reduces the response to 5-HT but 35 not to DMPP is believed to act as a 5-HT<sub>4</sub> receptor antagonist and a compound which increases the response to 5-HT but not to DMPP is believed to act as a 5-HT<sub>4</sub> receptor agonist.

- 6 -

2) Rat oesophagus

Rat oesophageal tunica muscularis mucosae is set up according to Baxter *et al.* Naunyn-Schmiedeberg's Arch. Pharmacol., 343, 439-446 (1991). The 5 inner smooth muscle tube of the tunica muscularis mucosae is isolated and mounted for isometric tension recording in oxygenated (95% O<sub>2</sub>/5% CO<sub>2</sub>) Tyrodes solution at 37°C. All experiments are performed in pargyline pre-treated preparations (100μM for 15 min followed by washout) and in the presence of cocaine (30μM). Relaxant responses to 5-HT are obtained after 10 pre-contracting the oesophagus tissue with carbachol (3μM).

**Claims**

1. A method for the treatment and/or prophylaxis of conditions associated with bladder hypersensitivity and conditions associated with a poorly functioning bladder in mammals, including humans, which method comprises administering to the mammal in need of such treatment and/or prophylaxis, an effective and/or prophylactic amount of a 5-HT<sub>4</sub> modulator.
2. The use of a 5-HT<sub>4</sub> modulator in the manufacture of a medicament for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity.
3. A pharmaceutical composition for use in the treatment and/or prophylaxis of conditions associated with a poorly functioning bladder and bladder hypersensitivity, which comprises a 5-HT<sub>4</sub> modulator, and a pharmaceutically acceptable carrier.
4. A method, use or composition according to claim 1, 2 or 3 wherein the 5-HT<sub>4</sub> modulator is a 5-HT<sub>4</sub> receptor antagonist.
5. A method, use or composition according to claim 4 for the treatment of urinary incontinence.
6. A method, use or composition according to claim 5 for the treatment of urinary incontinence associated with irritable bowel syndrome.
7. A method, use or composition according to claim 4, 5 or 6 wherein 5-HT<sub>4</sub> receptor antagonist is R 50 595, SDZ 205-557, DAU 6285, RS 23597-190 or a compound described in relation to EP-A-501322 (Glaxo Group Limited).
8. A method, use or composition according to claim 1, 2 or 3 wherein the 5-HT<sub>4</sub> modulator is a 5-HT<sub>4</sub> receptor agonist.
9. A method, use or composition according to claim 8 for the treatment of urinary bladder hypoactivity following prostatectomy.

- 8 -

10. A method, use or composition according to claim 8 or 9 wherein 5-HT<sub>4</sub> receptor agonist is cisapride, renzapride or zacopride.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/02376

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1. 5 A61K31/40; A61K31/445; A61K31/435

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.C1. 5	A61K

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
P, X	EP, A, 0 501 322 (GLAXO GROUP LTD) 2 September 1992 cited in the application see page 5, line 18 - line 37; claims 1-16 ---	1-7
P, X	EP, A, 0 467 365 (E.R. SQUIBB & SONS, INC.) 22 January 1992 see page 2, line 49 - page 3, line 56 ---	1-3, 8-10
X	PARAPLEGIA vol. 26, no. 3, 1988, pages 162 - 164; M. ETIENNE ET AL.: 'Treatment with cisapride of the gastrointestinal and urological sequelae of spinal cord transection: case report' see conclusion see abstract ---	1-3, 8-10

<sup>10</sup> Special categories of cited documents :<sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

15 MARCH 1993

Date of Mailing of this International Search Report

16.04.93.

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

TZSCHOPPE D. A.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category	Citation of Document, with indication, where appropriate, of the relevant passages	
X	PARAPLEGIA vol. 26, no. 3, 1988, pages 159 - 161; G.H. DE GROOT ET AL.: 'Effects of cisapride on constipation due to neurological lesion' see discussion see abstract ----	1-3,8-10
X	ACTA BELG. MED. PHYS. vol. 12, no. 3, 1989, pages 81 - 88; P.HANSON ET AL.: 'Effet du cisapride sur les vessies neurologiques' see conclusions ----	1-3,8-10
P,X	DRUG. DEV. RES. vol. 27, no. 4, 1992, pages 361 - 375; WILLIAM D. STEERS ET AL.: 'Effects of serotonergic agonists on micturition and sexual function in the rat' see abstract ----	1-3,8-10
A	DRUGS FUTURE vol. 16, no. 11, 1991, pages 1011 - 1026; M. TURCONI ET AL: 'Azabicycloalkyl benzimidazolones: Interaction with serotonergic 5-HT3 and 5-HT4 receptors and potential therapeutic implications' see the whole document ----	1-10

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

GB 9202376  
SA 68535

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 15/03/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0501322	02-09-92	AU-A-	1209492	15-09-92
		WO-A-	9214727	03-09-92
EP-A-0467365	22-01-92	CA-A-	2044854	20-01-92
		JP-A-	4234328	24-08-92